HRP20241527T1 - 1-[1-(4-benziloksi-3,5-difluorbenzoil)-4-fluorpirolidin-2-karbonil]pirolidin-2-karbonitril - Google Patents
1-[1-(4-benziloksi-3,5-difluorbenzoil)-4-fluorpirolidin-2-karbonil]pirolidin-2-karbonitril Download PDFInfo
- Publication number
- HRP20241527T1 HRP20241527T1 HRP20241527TT HRP20241527T HRP20241527T1 HR P20241527 T1 HRP20241527 T1 HR P20241527T1 HR P20241527T T HRP20241527T T HR P20241527TT HR P20241527 T HRP20241527 T HR P20241527T HR P20241527 T1 HRP20241527 T1 HR P20241527T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- formula
- pyrrolidine
- carbonitrile
- benzyloxy
- Prior art date
Links
- PITYBXLIZJGHLY-UHFFFAOYSA-N 1-[1-(3,5-difluoro-4-phenylmethoxybenzoyl)-4-fluoropyrrolidine-2-carbonyl]pyrrolidine-2-carbonitrile Chemical compound N#CC(CCC1)N1C(C(CC(C1)F)N1C(C(C=C1F)=CC(F)=C1OCC1=CC=CC=C1)=O)=O PITYBXLIZJGHLY-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 19
- 150000003839 salts Chemical class 0.000 claims 5
- 208000010877 cognitive disease Diseases 0.000 claims 3
- 238000006243 chemical reaction Methods 0.000 claims 2
- PITYBXLIZJGHLY-DBXWQHBBSA-N (2R)-1-[(2R,4R)-1-(3,5-difluoro-4-phenylmethoxybenzoyl)-4-fluoropyrrolidine-2-carbonyl]pyrrolidine-2-carbonitrile Chemical compound N#C[C@@H](CCC1)N1C([C@@H](C[C@H](C1)F)N1C(C(C=C1F)=CC(F)=C1OCC1=CC=CC=C1)=O)=O PITYBXLIZJGHLY-DBXWQHBBSA-N 0.000 claims 1
- PITYBXLIZJGHLY-WAOWUJCRSA-N (2R)-1-[(2R,4S)-1-(3,5-difluoro-4-phenylmethoxybenzoyl)-4-fluoropyrrolidine-2-carbonyl]pyrrolidine-2-carbonitrile Chemical compound N#C[C@@H](CCC1)N1C([C@@H](C[C@@H](C1)F)N1C(C(C=C1F)=CC(F)=C1OCC1=CC=CC=C1)=O)=O PITYBXLIZJGHLY-WAOWUJCRSA-N 0.000 claims 1
- PITYBXLIZJGHLY-OPYAIIAOSA-N (2R)-1-[(2S,4R)-1-(3,5-difluoro-4-phenylmethoxybenzoyl)-4-fluoropyrrolidine-2-carbonyl]pyrrolidine-2-carbonitrile Chemical compound N#C[C@@H](CCC1)N1C([C@H](C[C@H](C1)F)N1C(C(C=C1F)=CC(F)=C1OCC1=CC=CC=C1)=O)=O PITYBXLIZJGHLY-OPYAIIAOSA-N 0.000 claims 1
- PITYBXLIZJGHLY-UEXGIBASSA-N (2R)-1-[(2S,4S)-1-(3,5-difluoro-4-phenylmethoxybenzoyl)-4-fluoropyrrolidine-2-carbonyl]pyrrolidine-2-carbonitrile Chemical compound N#C[C@@H](CCC1)N1C([C@H](C[C@@H](C1)F)N1C(C(C=C1F)=CC(F)=C1OCC1=CC=CC=C1)=O)=O PITYBXLIZJGHLY-UEXGIBASSA-N 0.000 claims 1
- PITYBXLIZJGHLY-LVCYWYKZSA-N (2S)-1-[(2R,4R)-1-(3,5-difluoro-4-phenylmethoxybenzoyl)-4-fluoropyrrolidine-2-carbonyl]pyrrolidine-2-carbonitrile Chemical compound N#C[C@H](CCC1)N1C([C@@H](C[C@H](C1)F)N1C(C(C=C1F)=CC(F)=C1OCC1=CC=CC=C1)=O)=O PITYBXLIZJGHLY-LVCYWYKZSA-N 0.000 claims 1
- PITYBXLIZJGHLY-BBTUJRGHSA-N (2S)-1-[(2R,4S)-1-(3,5-difluoro-4-phenylmethoxybenzoyl)-4-fluoropyrrolidine-2-carbonyl]pyrrolidine-2-carbonitrile Chemical compound N#C[C@H](CCC1)N1C([C@@H](C[C@@H](C1)F)N1C(C(C=C1F)=CC(F)=C1OCC1=CC=CC=C1)=O)=O PITYBXLIZJGHLY-BBTUJRGHSA-N 0.000 claims 1
- PITYBXLIZJGHLY-LQWHRVPQSA-N (2S)-1-[(2S,4R)-1-(3,5-difluoro-4-phenylmethoxybenzoyl)-4-fluoropyrrolidine-2-carbonyl]pyrrolidine-2-carbonitrile Chemical compound N#C[C@H](CCC1)N1C([C@H](C[C@H](C1)F)N1C(C(C=C1F)=CC(F)=C1OCC1=CC=CC=C1)=O)=O PITYBXLIZJGHLY-LQWHRVPQSA-N 0.000 claims 1
- PITYBXLIZJGHLY-WFXMLNOXSA-N (2S)-1-[(2S,4S)-1-(3,5-difluoro-4-phenylmethoxybenzoyl)-4-fluoropyrrolidine-2-carbonyl]pyrrolidine-2-carbonitrile Chemical compound N#C[C@H](CCC1)N1C([C@H](C[C@@H](C1)F)N1C(C(C=C1F)=CC(F)=C1OCC1=CC=CC=C1)=O)=O PITYBXLIZJGHLY-WFXMLNOXSA-N 0.000 claims 1
- 208000017194 Affective disease Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000025535 REM sleep behavior disease Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 125000005392 carboxamide group Chemical group NC(=O)* 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- 208000024714 major depressive disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002560 nitrile group Chemical group 0.000 claims 1
- 238000005580 one pot reaction Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20382606 | 2020-07-07 | ||
| EP21739678.7A EP4178945B1 (en) | 2020-07-07 | 2021-07-06 | 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile |
| PCT/EP2021/068577 WO2022008477A1 (en) | 2020-07-07 | 2021-07-06 | 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20241527T1 true HRP20241527T1 (hr) | 2025-01-03 |
Family
ID=71607883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20241527TT HRP20241527T1 (hr) | 2020-07-07 | 2021-07-06 | 1-[1-(4-benziloksi-3,5-difluorbenzoil)-4-fluorpirolidin-2-karbonil]pirolidin-2-karbonitril |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US12459891B2 (enExample) |
| EP (1) | EP4178945B1 (enExample) |
| JP (1) | JP7628716B2 (enExample) |
| KR (1) | KR20230035604A (enExample) |
| CN (1) | CN117545738A (enExample) |
| AU (1) | AU2021303440A1 (enExample) |
| BR (1) | BR112023000335A2 (enExample) |
| CA (1) | CA3185064A1 (enExample) |
| ES (1) | ES2997164T3 (enExample) |
| HR (1) | HRP20241527T1 (enExample) |
| HU (1) | HUE068953T2 (enExample) |
| IL (1) | IL299035B1 (enExample) |
| MA (1) | MA60250B1 (enExample) |
| MX (1) | MX2023000261A (enExample) |
| RS (1) | RS66215B1 (enExample) |
| SM (1) | SMT202400460T1 (enExample) |
| TW (1) | TWI893162B (enExample) |
| WO (1) | WO2022008477A1 (enExample) |
| ZA (1) | ZA202213708B (enExample) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6159938A (en) | 1994-11-21 | 2000-12-12 | Cortech, Inc. | Serine protease inhibitors comprising α-keto heterocycles |
| DE19603510A1 (de) | 1996-02-01 | 1997-08-07 | Knoell Hans Forschung Ev | Die Verwendung von Terrecyclolsäure A und Terrecyclolsäure A-Derivate als neue Inhibitoren der humanen Prolyl-Oligopeptidase |
| FI20011466A0 (fi) | 2001-07-04 | 2001-07-04 | Orion Corp | Prolyylioligopeptidaasia inhiboivaa aktiivisuutta omaavia yhdisteitä, niiden valmistusmenetelmiä ja käyttö |
| FI20030014A0 (fi) | 2003-01-03 | 2003-01-03 | Orion Corp | Prolyylioligopeptidaasia inhiboivaa aktiivisuutta omaavia yhdisteitä |
| FI20031018A0 (fi) | 2003-07-04 | 2003-07-04 | Orion Corp | Parannus aivovammasta toipumiseen |
| WO2005027934A1 (ja) | 2003-09-24 | 2005-03-31 | Nippon Kayaku Kabushiki Kaisha | プロリルオリゴペプチダーゼ阻害剤 |
| US7667044B2 (en) | 2003-11-03 | 2010-02-23 | Probiodrug Ag | Compounds for the treatment of neurological disorders |
| ES2302473B1 (es) | 2006-12-22 | 2009-06-12 | Universidad De Barcelona | Agente terapeutico para el tratamiento del desorden afectivo bipolar en mamiferos. |
| EP2730571A1 (en) * | 2012-11-12 | 2014-05-14 | Universitat De Barcelona | 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives |
-
2021
- 2021-07-06 AU AU2021303440A patent/AU2021303440A1/en active Pending
- 2021-07-06 RS RS20241253A patent/RS66215B1/sr unknown
- 2021-07-06 WO PCT/EP2021/068577 patent/WO2022008477A1/en not_active Ceased
- 2021-07-06 HR HRP20241527TT patent/HRP20241527T1/hr unknown
- 2021-07-06 MX MX2023000261A patent/MX2023000261A/es unknown
- 2021-07-06 TW TW110124773A patent/TWI893162B/zh active
- 2021-07-06 EP EP21739678.7A patent/EP4178945B1/en active Active
- 2021-07-06 HU HUE21739678A patent/HUE068953T2/hu unknown
- 2021-07-06 JP JP2022581707A patent/JP7628716B2/ja active Active
- 2021-07-06 CA CA3185064A patent/CA3185064A1/en active Pending
- 2021-07-06 SM SM20240460T patent/SMT202400460T1/it unknown
- 2021-07-06 CN CN202180047448.7A patent/CN117545738A/zh active Pending
- 2021-07-06 US US18/004,658 patent/US12459891B2/en active Active
- 2021-07-06 MA MA60250A patent/MA60250B1/fr unknown
- 2021-07-06 ES ES21739678T patent/ES2997164T3/es active Active
- 2021-07-06 BR BR112023000335A patent/BR112023000335A2/pt unknown
- 2021-07-06 KR KR1020237003988A patent/KR20230035604A/ko active Pending
-
2022
- 2022-12-12 IL IL299035A patent/IL299035B1/en unknown
- 2022-12-19 ZA ZA2022/13708A patent/ZA202213708B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202213708B (en) | 2024-04-24 |
| IL299035A (en) | 2023-02-01 |
| TWI893162B (zh) | 2025-08-11 |
| JP7628716B2 (ja) | 2025-02-12 |
| SMT202400460T1 (it) | 2025-01-14 |
| EP4178945B1 (en) | 2024-08-28 |
| BR112023000335A2 (pt) | 2023-01-31 |
| US12459891B2 (en) | 2025-11-04 |
| AU2021303440A1 (en) | 2023-02-02 |
| CN117545738A (zh) | 2024-02-09 |
| EP4178945C0 (en) | 2024-08-28 |
| US20230250058A1 (en) | 2023-08-10 |
| WO2022008477A1 (en) | 2022-01-13 |
| ES2997164T3 (en) | 2025-02-14 |
| EP4178945A1 (en) | 2023-05-17 |
| CA3185064A1 (en) | 2022-01-13 |
| HUE068953T2 (hu) | 2025-02-28 |
| MX2023000261A (es) | 2023-04-13 |
| JP2023533932A (ja) | 2023-08-07 |
| MA60250B1 (fr) | 2024-11-29 |
| TW202216689A (zh) | 2022-05-01 |
| KR20230035604A (ko) | 2023-03-14 |
| IL299035B1 (en) | 2026-03-01 |
| RS66215B1 (sr) | 2024-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60028045T2 (de) | Neue bernsteinsäure derivative als cysteine-protease-inhibitoren | |
| DE602004010829T2 (de) | Adamantan- und azabicyclooctan- und -nonanderivate, verfahren zu deren herstellung und deren verwendung als dpp-iv-inhibitoren | |
| JP5550650B2 (ja) | 細菌感染症処置に適用するための有機化合物 | |
| CN1041827C (zh) | 被取代的3－氨基奎宁环化合物的制备方法 | |
| JP2006022107A5 (enExample) | ||
| JP2022515293A5 (enExample) | ||
| JP2008514627A5 (enExample) | ||
| JP2006503807A5 (enExample) | ||
| CN1085659C (zh) | 2－(4－取代)－苄基氨基－2－甲基－丙酰胺衍生物 | |
| SG181874A1 (en) | Substituted benzamide derivatives | |
| RU2010119528A (ru) | Замещенные n-фенилбипирролидинкарбоксамиды и их применение в лечебных целях | |
| CN1283183A (zh) | 具有mmp和tnf抑制活性的异羟肟酸和羧酸衍生物 | |
| CN102482203B (zh) | 碳环glyt1受体拮抗剂 | |
| JP2007291124A (ja) | α２δ−タンパク質に親和性を有するアミノ酸 | |
| EP1876168B1 (de) | Verfahren zur Herstellung von beta-Amino-alpha-hydroxy-carbonsäureamiden | |
| ME02706B (me) | Derivati 1·[1-(benzoil)-pirolidin-2-karbonil] -pirolidin-2-karbonitrila | |
| AR051919A1 (es) | Compuesto derivado de benzazepina, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y procedimientos para preparar el compuesto | |
| DE69621877T2 (de) | 4-Indolylpiperazinyl-Derivate | |
| US7160907B2 (en) | Pleuromutilin derivatives | |
| JP2015536965A5 (enExample) | ||
| IL299035A (en) | 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile | |
| MX2025010948A (es) | Derivados fusionados con tiofeno sustituido, composiciones que los comprenden y su uso como productos farmacéuticos | |
| US10273213B2 (en) | Method for the production of praziquantel and precursors thereof | |
| JP2023533932A5 (enExample) | ||
| JP2019535715A5 (enExample) |